Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adaptimmune Therapeutics PLCADAP · Entity 9824 | Director · Chief Executive Officer | February 20, 2025 | February 20, 2025 |
| Wave Life Sciences, Inc.WVE · Entity 4976 | Director | October 05, 2026 | October 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adaptimmune Therapeutics PLC
Report date February 20, 2025 · Filed February 20, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $0.10 · Expires 2035-02-20 | Direct | 5,143,248 |
Reported balance
After 2025-02-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-02-20 · Grant · Acquired 5,143,248 · Balance 5,143,248 F1: The exercise price was converted from GBP0.08 based on an exchange rate of U.S.$ 1.257137 to GBP1.00. The actual exercise price will be the pounds sterling amount. F2: Exercisable as to 1,285,812 Ordinary Shares on February 20, 2026 and will be exercisable as to the remainder in monthly installments of 107,148 Ordinary Shares on the twentieth of each month from March 20, 2026 through January 20, 2028 and 107,256 Ordinary Shares on February 20, 2029. |
| Option to purchase Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 3,428,832 |
Reported balance
After 2025-02-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-02-20 · Grant · Acquired 3,428,832 · Balance 3,428,832 F3: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.257137 to GBP1.00. The actual exercise price will be the pounds sterling amount. F4: Exercisable as to 857,208 Ordinary Shares on February 20, 2026 and will be exercisable as to the remainder in annual installments of 857,208 Ordinary Shares on the twentieth of each February from February 20, 2027 through February 20, 2029. F5: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price was converted from GBP0.08 based on an exchange rate of U.S.$ 1.257137 to GBP1.00. The actual exercise price will be the pounds sterling amount.
F2: Exercisable as to 1,285,812 Ordinary Shares on February 20, 2026 and will be exercisable as to the remainder in monthly installments of 107,148 Ordinary Shares on the twentieth of each month from March 20, 2026 through January 20, 2028 and 107,256 Ordinary Shares on February 20, 2029.
F3: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.257137 to GBP1.00. The actual exercise price will be the pounds sterling amount.
F4: Exercisable as to 857,208 Ordinary Shares on February 20, 2026 and will be exercisable as to the remainder in annual installments of 857,208 Ordinary Shares on the twentieth of each February from February 20, 2027 through February 20, 2029.
F5: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.
Wave Life Sciences, Inc.
Report date October 05, 2026 · Filed October 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,700 |
Reported balance
After 2026-10-05 transaction · row 1
1 source rowRow 1 · 2026-10-05 · Grant · Acquired 10,700 · Balance 10,700 F1: The reporting person was granted this restricted stock unit award (RSU) pursuant to the 2026 Non-Employee Director Compensation Policy. The RSU vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.75 · Expires 2036-10-05 | Direct | 64,000 |
Reported balance
After 2026-10-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-10-05 · Grant · Acquired 64,000 · Balance 64,000 F2: The reporting person was granted this option pursuant to the 2026 Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person was granted this restricted stock unit award (RSU) pursuant to the 2026 Non-Employee Director Compensation Policy. The RSU vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027.
F2: The reporting person was granted this option pursuant to the 2026 Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 18, 2020 Filed Aug 20, 2020 22:32 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 10,500 | $0.00 Strike: $9.13 | $0.00 |
DisclosureSEC source: 0000899243-20-023085 · doc4.xml · derivative · entry 1 Rawcliffe Adrian · CIK 0001555851 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Ordinary Shares · 10,500 shares Expires 2025-08-18 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2021 annual general meeting or August 18, 2021. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 01:01 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | SaleAmerican Depositary Shares representing Ordinary Shares | 2,788 | $9.25 | $25,789.00 |
DisclosureSEC source: 0001104659-20-090468 · a4.xml · nonDerivative · entry 1 Rawcliffe Adrian · CIK 0001555851 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,064 F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on June 27, 2019 and which vested on June 27, 2020. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person. F2 · price: These ADSs were sold in multiple transactions at a price of $9.25. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote. F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 12,288 ADSs and RSU-style options and other options covering an aggregate of 12,827,004 ordinary shares of the Issuer. Read SEC document |
| January 16, 2020 Filed Jan 18, 2020 02:30 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 561,792 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-005256 · a4.xml · derivative · entry 2 Rawcliffe Adrian · CIK 0001555851 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 561,792 Underlying: Ordinary Shares · 561,792 shares Expires not disclosed F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.302659 to GBP1.00. The actual exercise price will be the pounds sterling amount. F4 · derivative.exercise_date: Exercisable as to 140,448 Ordinary Shares on January 16, 2021 and will be exercisable as to the remainder in annual installments of 140,448 Ordinary Shares on the sixteenth of each January from January 16, 2022 through January 16, 2024. F5 · derivative.expiration_date: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable. Read SEC document |
| January 16, 2020 Filed Jan 18, 2020 02:30 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 2,515,536 | $0.00 Strike: $0.74 | $0.00 |
DisclosureSEC source: 0001104659-20-005256 · a4.xml · derivative · entry 1 Rawcliffe Adrian · CIK 0001555851 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,515,536 Underlying: Ordinary Shares · 2,515,536 shares Expires 2030-01-16 F1 · derivative.exercise_price: The exercise price was converted from GBP0.57 based on an exchange rate of $U.S. 1.302659 to GBP1.00. The actual exercise price will be the pounds sterling amount. F2 · derivative.exercise_date: Exercisable as to 628,884 Ordinary Shares on January 16, 2021 and will be exercisable as to the remainder in monthly installments of 52,404 Ordinary Shares on the sixteenth of each month from February 16, 2021 through December 16, 2023 and 52,512 Ordinary Shares on January 16, 2024. Read SEC document |
| January 14, 2020 Filed Jan 16, 2020 01:01 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | SaleAmerican Depositary Shares representing Ordinary Shares | 3,236 | $5.13 | $16,615.89 |
DisclosureSEC source: 0001104659-20-004420 · a4.xml · nonDerivative · entry 1 Rawcliffe Adrian · CIK 0001555851 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,166 F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2018 and which vested on January 12, 2020. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $5.12 to $5.18, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote. F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 9,122 ADSs and RSU-style options and other options covering an aggregate of 9,784,788 ordinary shares of the Issuer. Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 01:00 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | SaleAmerican Depositary Shares representing Ordinary Shares | 5,900 | $1.20 | $7,080.00 |
DisclosureSEC source: 0001104659-20-002080 · a4.xml · nonDerivative · entry 1 Rawcliffe Adrian · CIK 0001555851 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,804 F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 4, 2019 and which vested on January 4, 2020. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $1.20 to $1.2008, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote. F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 3,318 ADSs and RSU-style options and other options covering an aggregate of 9,823,200 ordinary shares of the Issuer. Read SEC document |
| September 01, 2019 Filed Sep 4, 2019 01:00 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 140,448 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-048518 · a4.xml · derivative · entry 2 Rawcliffe Adrian · CIK 0001555851 · Director · CEO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,448 Underlying: Ordinary Shares · 140,448 shares Expires not disclosed F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.21721 to GBP1.00. The actual exercise price will be the pounds sterling amount. F4 · derivative.exercise_date: Exercisable as to 35,112 Ordinary Shares on September 1, 2020 and will be exercisable as to the remainder in annual installments of 35,112 Ordinary Shares on the first of each September from September 1, 2021 through September 1, 2023. F5 · derivative.expiration_date: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable. Read SEC document |
| September 01, 2019 Filed Sep 4, 2019 01:00 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 628,872 | $0.00 Strike: $0.27 | $0.00 |
DisclosureSEC source: 0001104659-19-048518 · a4.xml · derivative · entry 1 Rawcliffe Adrian · CIK 0001555851 · Director · CEO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 628,872 Underlying: Ordinary Shares · 628,872 shares Expires 2029-09-01 F1 · derivative.exercise_price: The exercise price was converted from GBP0.22 based on an exchange rate of $U.S. 1.21721 to GBP1.00. The actual exercise price will be the pounds sterling amount. F2 · derivative.exercise_date: Exercisable as to 157,218 Ordinary Shares on September 1, 2020 and will be exercisable as to the remainder in monthly installments of 13,101 Ordinary Shares on the first of each month from October 1, 2020 through August 1, 2023 and 13,119 Ordinary Shares on September 1, 2023. Read SEC document |
| August 15, 2019 Filed Aug 16, 2019 20:20 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 10,500 | $0.00 Strike: $20.34 | $0.00 |
DisclosureSEC source: 0000899243-19-021965 · doc4.xml · derivative · entry 1 Rawcliffe Adrian · CIK 0001555851 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Ordinary Shares · 10,500 shares Expires 2024-08-15 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2020 annual general meeting or August 15, 2020 Read SEC document |
| June 27, 2019 Filed Jun 28, 2019 00:00 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 140,448 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-038003 · a4.xml · derivative · entry 2 Rawcliffe Adrian · CIK 0001555851 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,448 Underlying: Ordinary Shares · 140,448 shares Expires not disclosed F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.26828 - GBP1.00. The actual exercise price will be the pounds sterling amount. F4 · derivative.exercise_date: Exercisable as to 35,112 Ordinary Shares on June 27, 2020 and will be exercisable as to the remainder in annual installments of 35,112 Ordinary Shares on the twenty-seventh of each June from June 27, 2021 through June 27, 2023. F5 · derivative.expiration_date: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable. Read SEC document |
| June 27, 2019 Filed Jun 28, 2019 00:00 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 628,872 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001104659-19-038003 · a4.xml · derivative · entry 1 Rawcliffe Adrian · CIK 0001555851 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 628,872 Underlying: Ordinary Shares · 628,872 shares Expires 2029-06-27 F1 · derivative.exercise_price: The exercise price was converted from GBP0.53 based on an exchange rate of $U.S. 1.26828 - GBP1.00. The actual exercise price will be the pounds sterling amount. F2 · derivative.exercise_date: Exercisable as to 157,218 Ordinary Shares on June 27, 2020 and will be exercisable as to the remainder in monthly installments of 13,101 Ordinary Shares on the twenty-seventh of each month from July 27, 2020 through May 27, 2022 and 13,119 Ordinary Shares on June 27, 2023. Read SEC document |
| January 14, 2019 Filed Jan 17, 2019 02:30 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | SaleAmerican Depositary Shares representing Ordinary Shares | 3,084 | $5.37 | $16,559.23 |
DisclosureSEC source: 0001104659-19-002163 · a4.xml · nonDerivative · entry 1 Rawcliffe Adrian · CIK 0001555851 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,318 F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2018 and which vested on January 12, 2019. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $5.21 to $5.70, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote. F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds RSU-style options and other options covering an aggregate of 8,354,784 ordinary shares of the Issuer. Read SEC document |
| January 04, 2019 Filed Jan 9, 2019 02:01 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 280,896 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-001302 · a4.xml · derivative · entry 2 Rawcliffe Adrian · CIK 0001555851 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,896 Underlying: Ordinary Shares · 280,896 shares Expires not disclosed F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.26332 - GBP1.00. The actual exercise price will be the pounds sterling amount. F4 · derivative.exercise_date: Exercisable as to 70,224 Ordinary Shares on January 4, 2020 and will be exercisable as to the remainder in annual installments of 70,224 Ordinary Shares on the fourth of each January from January 4, 2021 through January 4, 2023. F5 · derivative.expiration_date: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable. Read SEC document |
| January 04, 2019 Filed Jan 9, 2019 02:01 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 1,257,744 | $0.00 Strike: $0.89 | $0.00 |
DisclosureSEC source: 0001104659-19-001302 · a4.xml · derivative · entry 1 Rawcliffe Adrian · CIK 0001555851 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,257,744 Underlying: Ordinary Shares · 1,257,744 shares Expires 2029-01-04 F1 · derivative.exercise_price: The exercise price was converted from GBP0.70 based on an exchange rate of $U.S. 1.26332 - GBP1.00. The actual exercise price will be the pounds sterling amount. F2 · derivative.exercise_date: Exercisable as to 314,436 Ordinary Shares on January 4, 2020 and will be exercisable as to the remainder in monthly installments of 26,202 Ordinary Shares on the fourth of each month from February 4, 2020 through December 4, 2022 and 26,238 Ordinary Shares on January 4, 2023. Read SEC document |
| August 13, 2018 Filed Aug 16, 2018 00:03 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 9,000 | $0.00 Strike: $46.70 | $0.00 |
DisclosureSEC source: 0000899243-18-022506 · doc4.xml · derivative · entry 1 Rawcliffe Adrian · CIK 0001555851 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Ordinary Shares · 9,000 shares Expires 2023-08-13 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on August 13, 2019. Read SEC document |
| March 20, 2018 Filed Mar 23, 2018 01:01 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | SaleOrdinary Shares | 600,000 | $1.71 | $1,026,000.00 |
DisclosureSEC source: 0001104659-18-019665 · a4.xml · nonDerivative · entry 1 Rawcliffe Adrian · CIK 0001555851 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: The Ordinary Shares whose sale is reported on this line are represented by American Depositary Shares ("ADSs"). Each ADS represents six Ordinary Shares. The Ordinary Shares were obtained from the partial exercise of an option that was granted on March 16, 2015. F1 · shares: The Ordinary Shares whose sale is reported on this line are represented by American Depositary Shares ("ADSs"). Each ADS represents six Ordinary Shares. The Ordinary Shares were obtained from the partial exercise of an option that was granted on March 16, 2015. F2 · price: The sale price of $1.71 per Ordinary Share was derived from the sale price of $10.27 per ADS on March 20, 2018 divided by six. Read SEC document |
| January 12, 2018 Filed Jan 17, 2018 22:21 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 153,648 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-002677 · a4.xml · derivative · entry 2 Rawcliffe Adrian · CIK 0001555851 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,648 Underlying: Ordinary Shares · 153,648 shares Expires not disclosed F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.3542 - GBP1.00. The actual exercise price will be the pounds sterling amount. F4 · derivative.exercise_date: Exercisable as to 38,412 Ordinary Shares on January 12, 2019 and will be exercisable as to the remainder in annual installments of 38,412 Ordinary Shares on the twelfth of each January from January 12, 2020 through January 12, 2022. F5 · derivative.expiration_date: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable. Read SEC document |
| January 12, 2018 Filed Jan 17, 2018 22:21 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 687,984 | $0.00 Strike: $1.30 | $0.00 |
DisclosureSEC source: 0001104659-18-002677 · a4.xml · derivative · entry 1 Rawcliffe Adrian · CIK 0001555851 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 687,984 Underlying: Ordinary Shares · 687,984 shares Expires 2028-01-12 F1 · derivative.exercise_price: The exercise price was converted from GBP0.96 based on an exchange rate of $U.S. 1.3542 - GBP1.00. The actual exercise price will be the pounds sterling amount. F2 · derivative.exercise_date: Exercisable as to 171,996 Ordinary Shares on January 12, 2019 and will be exercisable as to the remainder in monthly installments of 14,333 Ordinary Shares on the twelfth of each month from February 12, 2019 through January 12, 2022. Read SEC document |
| August 10, 2017 Filed Aug 17, 2017 20:21 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 9,000 | $0.00 Strike: $18.10 | $0.00 |
DisclosureSEC source: 0000899243-17-020604 · doc4.xml · derivative · entry 1 Rawcliffe Adrian · CIK 0001555851 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Ordinary Shares · 9,000 shares Expires 2022-08-10 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on August 10, 2018. Read SEC document |
| February 01, 2017 Filed Feb 1, 2017 23:39 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 18,000 | $0.00 Strike: $28.80 | $0.00 |
DisclosureSEC source: 0000899243-17-002388 · doc4.xml · derivative · entry 1 Rawcliffe Adrian · CIK 0001555851 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Ordinary Shares · 18,000 shares Expires 2022-02-01 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy.The option vests as to 25% of the shares on February 1, 2018 and vests as to an additional 2.0833% of the shares monthly thereafter until February 1, 2021. Read SEC document |
| January 13, 2017 Filed Jan 18, 2017 22:02 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 2,072,976 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0001104659-17-002824 · a4.xml · derivative · entry 1 Rawcliffe Adrian · CIK 0001555851 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,072,976 Underlying: Ordinary Shares · 2,072,976 shares Expires 2027-01-13 F1 · derivative.exercise_price: The exercise price was converted from GBP0.59 based on the closing midpoint exchange rate for the U.S. dollar on the day prior to the date of grant listed in the Financial Times. The actual exercise price will be the pounds sterling amount. F2 · derivative.exercise_date: Exercisable as to 518,244 Ordinary Shares on January 13, 2018 and will be exercisable as to the remainder in monthly installments of 43,187 Ordinary Shares on the thirteenth of each month from February 13, 2018 through January 13, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.